linjc16/ctgov huggingface dataset:
Splenic Artery Ligation and Portocaval Shunt in Small-for-size Syndrome

Study Overview
=================
Brief Summary
-----------------
Our study aimed at assessing the changes of portal vein pressure, portal vein flow and hepatic arterial flow (HAF) in liver remnants ≤ 30% of the standard liver volume by reducing portal vein overflow via ligation of the splenic artery.

Detailed Description
-----------------
It has been reported that prevention of acute portal overpressure in small-for-size liver grafts leads to better postoperative outcomes. Accordingly, we aimed to investigate the feasibility of the technique of splenic artery ligation in a case series of patients subjected to major liver resections with evidence of small-for-size syndrome and whether the maneuver results in reduction of portal venous pressure and flow.

Official Title
-----------------
Hemodynamic Modulations to Ameliorate Sinusoidal Injuries After Extended Liver Resections: the Role of Splenic Artery Ligation and Porto-caval Shunt in a Series of Patients

Conditions
-----------------
Small-For-Size Liver Syndrome, Ligation, Liver Regeneration, Splenic Artery, Portal Vein, Ischemia, Reperfusion Injury, Hepatectomy

Intervention / Treatment
-----------------
* Procedure: splenic artery ligation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients American Society of Anesthesiologists (ASA) distribution I to III Patients scheduled for major liver resection (≥4 segments) Exclusion Criteria: patients with extrahepatic disease patients with metastatic liver tumors

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: splenic artery ligation|We identified portal hyperperfusion as a cause of potential small-for-size liver remnant dysfunction and we applied splenic artery ligation as a technically simple procedure to manage the situation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| portal vein pressure | change of portal vein pressure from before liver resection to after reperfusion of the liver remnant | through the operation, an average period of two hours | 
| portal vein flow | change of portal vein flow from before liver resection to after reperfusion of the liver remnant | through the operation, an average period of two hours | 
| hepatic artery flow | change of hepatic artery flow from before liver resection to after reperfusion of the liver remnant | through the operation, an average period of two hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
small-for-size liver syndrome, ligation, splenic artery, hepatectomy, liver regeneration
Basic Life Support Cardiopulmonary Resuscitation Refresher in MS2 at St George's University

Study Overview
=================
Brief Summary
-----------------
175 second year medical students were assessed on their BLS CPR skill retention after an approximate one year after taking the initial certification class, and the investigators assessed which type of refresher course would be most effective in improving the students' CPR skills. Group 2 had no refresher, Group 3 had a multimedia refresher, and Group 4 had the same multimedia refresher plus hands on practice on a Laerdal BLS manikin. The investigators hypothesized that Group 4 would perform CPR skills with the highest competency compared to the other two groups.

Official Title
-----------------
Practical Skill Retention in Medical Students: Improving Cardiopulmonary Resuscitation With Hands-On Practice

Conditions
-----------------
Cardiopulmonary Resuscitation Skill Retention in Medical Students

Intervention / Treatment
-----------------
* Other: Multimedia
* Other: Hands-on practice


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Voluntary second year medical student

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Video refresher<br>Group 3, received 7 minute video refresher prior to examination. | Other: Multimedia<br>* AHA specific BLS refresher video, 7 minutes in length.<br>|
| Experimental: Video refresher and hands-on practice<br>Group 4, received same 7 minute video refresher, along with hands-on practice along with the video on a Laerdal BLS manikin. | Other: Multimedia<br>* AHA specific BLS refresher video, 7 minutes in length.<br>Other: Hands-on practice<br>* Hands-on BLS CPR practice on a Laerdal BLS manikin.<br>|
| No Intervention: No intervention<br>Group 2 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Chest compressions | Chest compressions were measured on a Laerdal Resusci-Anne recording manikin for each subject. | 1 session | 
| Bag Valve Mask ventilations | Bag Valve Mask ventilations were measured for each subject on a Laerdal Resusci-Anne recording manikin. | 1 session | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Eliciting which type of refresher provides the greatest improvement in BLS CPR skills.
Fibtem Predicts Postoperative Bleeding

Study Overview
=================
Brief Summary
-----------------
Retrospective study to evaluate if FIBTEM predicts the amount of postoperative bleeding in total knee replacement patients.

Detailed Description
-----------------
This retrospective study evaluate patients who underwent total knee replacement arthroplasty. Laboratory coagulation parameters, including FIBTEM, before anesthesia induction and after admission to the post-anesthetic care unit and decrement of postoperative haemoglobin and amount of transfusion were reviewed. A correlation coefficient of ρ = 0.4 was calculated from a pilot study. We need at least 44 subjects with an α value of 0.05 and a power of 0.8.

Official Title
-----------------
The Prediction of Postoperative Hemorrahge Amount in Total Knee Replacement Using Fibtem

Conditions
-----------------
Postoperative Hemorrhage

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who underwent primany unilateral total knee replacement arthroplasty under general anesthesia patients who had FIBTEM performed Exclusion Criteria: surgery under regional anaesthesia a simultaneous bilateral total knee replacement arthroplasty the second surgery of staged total knee replacement arthroplasty revision of total knee replacement arthroplasty patients who received intraoperative transfusion patients who use tranexamic acid patients who received fibrinolytic agents because of perioperative thromboembolic event patients who refused transfusion because of religious belief of personal causes

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| haemoglobin | the decrement of haemoglobin | postoperative periods | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fibtem, total knee replacement
Intracranial Stimulation Mapping In Epilepsy

Study Overview
=================
Brief Summary
-----------------
This is a single group prospective study to determine the feasibility for generating brain maps that localize cerebral functions and inter-regional information flow in partial epilepsy in adult patients.

Official Title
-----------------
Intracranial Stimulation Mapping In Epilepsy -The InStim Study

Conditions
-----------------
Epilepsy

Intervention / Treatment
-----------------
* Other: Functional mapping


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female 18 years and older at screening. Written informed consent is obtained from the participant to comply with the requirements of the study. Stated willingness to comply with all study procedures and availability for the duration of the study Currently undergoing clinically indicated intracranial EEG monitoring for planning of epilepsy surgery in the University of Minnesota/MINCEP program. Exclusion Criteria: Pregnancy ruled out prior to approval for intracranial EG monitoring. Persons who are rendered temporarily or permanently invulnerable by inability to understand the research due to study complexity, cognitive impairment, or by inability to make independent decisions owing to University of Minnesota or to Fairview health services.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Interventional Model Description: This is a single group prospective feasibility study on adult epilepsy patients evaluating whether study tasks and workflow are feasible
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Research IESM<br>Functional mapping for research application | Other: Functional mapping<br>* Intracranial EEG data acquisition, observation and behavioral testing, and intracranial electrical stimulation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The effect of prefrontal direct electrical brain stimulation on cognitive effort | The change in subjective value of cognitive effort (area under the curve) after direct electrical brain stimulation to different areas of the prefrontal cortex during an effortful task | Immediately after stimulation sessions |
Effects of Incomplete ERAS on Clinical Outcomes in Patients With Colorectal Cancer

Study Overview
=================
Brief Summary
-----------------
Enhanced recovery after surgery (ERAS) has been reported to be associated with improved outcomes in many studies, most of which involve short-term effects. Only a few studies have reported the long-term effects of highly compliant ERAS. However, to the best of our knowledge, there are no large-scale comparisons between incomplete ERAS (compliance < 70%) and non-ERAS. The aim of this comparative study is to analyze and evaluate the long-term outcomes of incomplete ERAS in laparoscopic colorectal cancer surgery.

Official Title
-----------------
Effects of Incomplete Enhanced Recovery After Surgery Program on Long-term Survival of Patients Undergoing Colorectal Cancer Surgery

Conditions
-----------------
Colorectal Neoplasms, Enhanced Recovery After Surgery

Intervention / Treatment
-----------------
* Procedure: ERAS protocol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. age older than 18 years;2. pathological diagnosis of colorectal cancer;3. radical surgery was performed; and 4. laparoscopic surgery was performed. Exclusion Criteria: 1. ERAS compliance ≥70%; 2. open surgery; 3. switch to laparotomy after laparoscopic surgery; 4. pregnancy or lactation; 5. severe mental illness; 6. Simultaneous malignant tumors of multiple organs; 7. History of other malignant tumors; and 8. Emergency radical colorectal resection due to obstruction, perforation or bleeding.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Incomplete ERAS<br>Incomplete ERAS was defined as ERAS compliance < 70%. | Procedure: ERAS protocol<br>* ERAS protocol is a series of procedures that enhance the recovery of surgical patients. Patients were grouped according to whether the procedure was attempted.<br>|
| Non-ERAS<br>non-ERAS was defined as not executing any ERAS programs. | Procedure: ERAS protocol<br>* ERAS protocol is a series of procedures that enhance the recovery of surgical patients. Patients were grouped according to whether the procedure was attempted.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| long-term survival | 5-year Disease free survival and overall survival | Each patient will be followed for 5 years or until death | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative complications | Postoperative complications within 30 days after surgery. | within 30 days after surgery |
Dexanabinol in Severe Traumatic Brain Injury

Study Overview
=================
Brief Summary
-----------------
Each year a large number of patients are hospitalized at Shock Trauma Centers with severe head injuries. Bleeding into and swelling of these patients' brains may cause compression of vital structures, disability and death. Sometimes surgery is needed. Unfortunately, the investigators have no medication to treat the bad effects of head trauma. Part of the brain damage is due to toxic chemicals (including one called glutamate) that are released by the damaged nerves. Dexanabinol may prevent some of the bad effects of glutamate on the brain and may protect the brain against uncontrollable swelling and death.

Detailed Description
-----------------
Dexanabinol is a synthetic, non-psychotropic cannabinoid derivative that because of its dextro-configuration is compatible with activation of cannabinoid receptors in the brain. It combines the ability to block NMDA receptors and neuroinflammatory cascades in the same molecule. Dexanabinol scavenges free radicals, protects neurons from toxicity of free radical generators and inhibits lipopolysaccharide-induced production of prostaglandin E2, NO and TNF-a by macrophages in culture.

Official Title
-----------------
Efficacy and Safety Evaluation of a Single Intravenous Dose of Dexanabinol in Patients Suffering From Severe Traumatic Brain Injury

Conditions
-----------------
Traumatic Brain Injury

Intervention / Treatment
-----------------
* Drug: Dexanabinol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Traumatic head injury within the last 6 hours Glasgow Coma Motor score of 2 to 5; severity requires intracranial pressure (ICP) monitoring Brain computed tomography (CT) showing intracranial parenchymal abnormality and hemodynamically stable An informed consent Exclusion Criteria: Penetrating head injury Spinal cord injury Coma due to pure epidural hematoma with initial Glasgow Coma Scale (GCS) of => 12 Previous major cerebral damage Concomitant severe conditions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Dexanabinol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glasgow Outcome Scale Extended (GOSE) at 6 months |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GOSE at 3 months |  |  | 
| Mortality rates at 10 days and 6 months |  |  | 
| Intracerebral pressure during first 72 hours of trauma |  |  | 
| Neuroworsening at 10 days |  |  | 
| Quality of life |  |  |
Management of Pain Respiratory Distress at the End of Life in Newborn Palliative Care in the Delivery Room

Study Overview
=================
Brief Summary
-----------------
The newborn feels pain and the newborn at the end of life, in the delivery room, is potentially exposed to pain and respiratory distress. Protocols for the management of end-of-life symptoms in the delivery room are used in current practice with very few validation studies. The protocol used in delivery rooms in Alsace uses fentanyl and midazolam intranasally. It has been used for 3 years and seems to provide satisfactory relief to newborn babies. In doing so, it seems to reassure parents about the quality of support and it seems to meet the expectations of professionals in these anxiety-provoking contexts. Scientific validation of these practices would allow wider dissemination to other maternity teams.

Official Title
-----------------
Management of Pain Respiratory Distress at the End of Life in Newborn Palliative Care in the

Conditions
-----------------
Respiratory Distress, Pain

Intervention / Treatment
-----------------
* Procedure: Protocols for the management of end-of-life symptoms


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Premature or term newborn In the delivery room In palliative care No parental opposition to data collection Exclusion Criteria: Parental refusal or inability to express their consent Minor parents Very probable survival beyond the delivery room Impossibility of giving informed information to the subject (subject in an emergency situation, difficulties in understanding the subject, etc.) Subject under safeguard of justice Subject under guardianship or curatorship
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Protocols for the management of end-of-life symptoms|Application of the care protocol and data collection|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in pain | Evaluate the effectiveness of the current protocol for the management of pain and discomfort related to end-of-life respiratory distress in newborns receiving palliative care in the delivery room with (Neonatal Facial Coding System) NFCS score | 1 day | 
| DRFV scores | Presence of DRFV with Silverman score | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
newborn
Intrathecal Administration of Baclofen (ITB) to Cerebral Palsy Patients With Therapy-Resistant Spasticity

Study Overview
=================
Brief Summary
-----------------
Evaluation of the effect of intrathecal administration of Baclofen on spasticity of cerebral palsy patients, by means of standardized and internationally accepted scales

Detailed Description
-----------------
Evaluation of the effect of intrathecal administration of Baclofen on spasticity of cerebral palsy patients, by means of standardized and internationally accepted scales

Official Title
-----------------
Intrathecal Administration of Baclofen (ITB) to Cerebral Palsy Patients With Therapy-Resistant Spasticity

Conditions
-----------------
Cerebral Palsy

Intervention / Treatment
-----------------
* Drug: Administration of intrathecal baclofen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CP patients with therapy-resistent spasticity Patients with sufficient body weight in relation to the volume Oral medication has failed: insufficient effect or too many side-effects The patient and family understand the objectives of the treatment and accept those objectives Informed Consent Exclusion Criteria: Contra-indications for surgery (e.g. infection) Hypersensitivity to oral Baclofen

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Administration of intrathecal baclofen|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Spasticity of patients after 4 years |  |  |
Statin and PAF in Patients With Pacemaker

Study Overview
=================
Brief Summary
-----------------
Statin could decrease AF burden

Detailed Description
-----------------
Statin could decrease AF burden in patients with PAF.

Official Title
-----------------
Atorvastatin Decreases Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

Conditions
-----------------
Paroxysmal Atrial Fibrillation

Intervention / Treatment
-----------------
* Drug: Statin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with pacemaker Exclusion Criteria: Patients with hepatic dysfunction

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Statin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |